Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 vs Pemetrexed Maintenance in Advanced Non-squamous NSCLC
NCT03700333Phase 3Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of tegafur in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression Free Survival at 1 year. Status: unknown.
02
Drugs
tegafur
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03700333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03700333.